Spectrum Pharmaceuticals, Inc. has launched a phase I/II trial in the United States to explore the safe and efficacious dose range of ozarelix (formerly SPI-153) as a treatment for patients with hormone-dependent prostate cancer.

"We are pleased to advance the development of ozarelix in the United States with the start of this clinical study," Rajesh Shrotriya, chairman of the Board, CEO and president of Spectrum Pharmaceuticals, Inc said adding, "This study will provide us additional valuable information regarding the optimum dose range for testosterone suppression, an important outcome measure in the management of hormone-dependent prostate cancer."

Ozarelix is a fourth generation LHRH (Luteinizing Hormone Releasing Hormone), also known as GnRH (Gonadotropin Releasing Hormone), antagonist. LHRH antagonists have the potential to treat hormone-dependent cancers as well as benign proliferative disorders such as benign prostatic hypertrophy and endometriosis. More information on ozarelix can be found in our annual report on Form 10-K filed with the Securities and Exchange Commission.

According to figures released by the American Cancer Society, approximately 232,090 new cases and 30,350 deaths will occur in the US during 2005. The initial treatment of prostate cancer included surgery along with radiation therapy and hormonal therapy.